文献速递自身炎症与 IgG4 相关病

IgG4相关葡萄膜炎:法国队列及文献综述

IgG4-related uveitis. A French cohort and literature review.
PubMed 文献 · Semin Arthritis Rheum · 2023-11-11

该研究基于法国全国IgG4相关病与系统性纤维化数据库及PubMed文献,纳入16例确诊IgG4相关病合并葡萄膜炎患者(数据库8例、文献8例),共30次葡萄膜炎发作。葡萄膜炎可为首发症状,随访中50%患者至少复发一次,三分之一患者需至少两种治疗线诱导缓解;作者认为可考虑早期使用激素节约剂。

要点

  • 葡萄膜炎可为首发症状,4/16例(25%)在其它IgG4相关症状前中位9个月出现。
  • 随访期间8/16例(50%)至少经历一次葡萄膜炎复发,三分之一患者需至少两种治疗线。
  • 激素单药治疗29次发作中28次(97%),16/28例(57%)获缓解。

核心结论

  • 葡萄膜炎可能是IgG4相关病的首发症状之一,在葡萄膜炎的诊断检查中应考虑IgG4相关病。
  • IgG4相关病中葡萄膜炎的早期出现可能有助于该病的早期诊断和治疗。
  • 激素单药治疗可能足以治疗IgG4相关葡萄膜炎,但复发频繁(50%),最终三分之一患者需至少两种治疗线。
  • 因此,可考虑在疾病早期使用激素节约剂,尤其是对于高复发风险或激素相关并发症风险高的患者。

研究设计与样本

  • 从法国全国IgG4相关病与系统性纤维化数据库中筛选葡萄膜炎且同时符合确诊IgG4相关病诊断标准(修订综合诊断标准、美国风湿病学会/欧洲抗风湿病联盟IgG4相关病分类标准、自身免疫性胰腺炎国际共识诊断标准或IgG4相关垂体炎诊断标准)的患者。
  • 同时进行PubMed文献综述,选取确诊IgG4相关病合并葡萄膜炎的病例。
  • 共报告16例患者(数据库8例、文献8例)和30次葡萄膜炎发作。

主要发现

  • 葡萄膜炎病例占全国IgG4相关病与系统性纤维化数据库中IgG4相关病患者的3%。
  • 葡萄膜炎在IgG4相关病中为首发表现者4/16例(25%),出现在任何其他IgG4相关症状之前,中位时间9个月。
  • 葡萄膜炎与其他IgG4相关症状同时出现者9/16例(56%),在IgG4相关病诊断前中位15个月。
  • 葡萄膜炎在随访期间出现者3/16例(19%),在首次IgG4相关症状后中位57个月;随访期间出现葡萄膜炎时,6/9例(67%)伴有其他器官IgG4相关病表现。
  • 葡萄膜炎双侧者8/16例(50%),肉芽肿性者5/10例(50%);前葡萄膜炎8/13例(62%),中间葡萄膜炎3/13例(23%),全葡萄膜炎4/13例(31%)。

关键数值与推荐

  • 诊断时血清IgG4中位值为3.2 g/L。
  • 中位随访时间6年,期间8/16例(50%)至少经历一次葡萄膜炎复发。
  • 29/30次葡萄膜炎发作有治疗数据;激素用于28/29次发作(97%),16/28例(57%)葡萄膜炎缓解。
  • 甲氨蝶呤联合全身激素作为二线或三线治疗用于6/29次发作(21%),4/6例(67%)葡萄膜炎缓解。
  • 利妥昔单抗联合全身激素作为二线或三线治疗用于5/29次发作(17%),4/5例(80%)葡萄膜炎缓解。

临床怎么用

  • 在葡萄膜炎的诊断检查中应考虑IgG4相关病。
  • 激素单药治疗可能足以治疗IgG4相关葡萄膜炎,但复发频繁(50%),最终三分之一患者需至少两种治疗线。
  • 作者认为,可考虑在疾病早期使用激素节约剂,尤其是对于高复发风险或激素相关并发症风险高的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect almost any organ. IgG4-related ophthalmic disease is a protean condition involving the orbit and ocular adnexa. Although a few cases of uveitis have been reported, the exact pattern of IgG4-related intraocular manifestations remains unclear. Here, we report on a nationwide French multicenter cohort of patients with IgG4-RD and uveitis and conducted a literature review. METHODS: Patients with uveitis and a concomitant definite diagnosis of IgG4-RD (Revised Comprehensive Diagnostic criteria, American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-RD, International Consensus Diagnostic Criteria for auto-immune pancreatitis, or diagnostic criteria for IgG4-related hypophysitis), were screened from our national IgG4-RD and systemic fibrosis database. Concomitantly, we conducted a PubMed literature review and selected cases of definite IgG4-RD with uveitis. RESULTS: We reported on 16 patients (8 from our database and 8 from the literature) and a total of 30 episodes of uveitis. Uveitis cases represented 3 % of total IgG4-RD patients in the national database on IgG4-RD and systemic fibrosis. Uveitis was inaugural in IgG4-RD in 4/16 cases (25 %) (appearing before any other IgG4-related symptom, at a median of 9 months), occurred concurrently to other IgG4-related symptoms in 9/16 cases (56 %) (at a median of 15 months before IgG4-RD diagnosis), and appeared during follow up in 3/16 patients (19 %) (at a median of 57 months after first IgG4-related symptoms). When uveitis occurred during follow up, it was associated with IgG4-RD manifestations in other organs in 6/9 patients (67 %). Uveitis was bilateral in 8/16 cases (50 %) and granulomatous in 5/10 cases (50 %). It was anterior in 8/13 (62 %), intermediate in 3/13 (23 %), and global (panuveitis) in 4/13 patients (31 %). Median serum IgG4 at diagnosis was 3.2 g/L. Median follow up time was of 6 years, during which 8/16 patients (50 %) experienced at least one relapse of uveitis. Treatment data was available for 29/30 uveitis flares. Steroids were used in 28/29 episodes of uveitis (97 %), leading to remission of uveitis in 16/28 cases (57 %). Methotrexate and rituximab (in combination with systemic steroids) were administered as second- or third-line therapy in 6/29 (21 %) and 5/29 (17 %) episodes of uveitis, respectively, and led to remission of uveitis in 4/6 cases (67 %) and 4/5 cases (80 %), respectively. One third of uveitides required at least two different lines of treatment for remission induction (mainly a combination of both systemic steroids and methotrexate or rituximab). DISCUSSION AND CONCLUSIONS: Uveitis may be one of the initial symptoms of IgG4-RD, and IgG4-RD should be considered in the diagnostic workup of uveitis. Its early onset in IgG4-RD may help with early diagnosis and treatment of the disease. Steroid monotherapy may be sufficient to treat IgG4-related uveitis, yet relapses were frequent (50 %) and ultimately a third of patients required at least two lines of treatment. Hence, steroid-sparing agents can be considered at early stages of the disease, particularly for patients with a high risk of relapse or steroid-related complications.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Stuchfield-Denby E, De Sainte Marie B, Hie M, et al. IgG4-related uveitis. A French cohort and literature review. Semin Arthritis Rheum. 2023. PMID: 38000318. doi:10.1016/j.semarthrit.2023.152278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。